estrone has been researched along with Uterine Prolapse in 4 studies
Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.
Uterine Prolapse: Downward displacement of the UTERUS. It is classified in various degrees: in the first degree the UTERINE CERVIX is within the vaginal orifice; in the second degree the cervix is outside the orifice; in the third degree the entire uterus is outside the orifice.
Excerpt | Relevance | Reference |
---|---|---|
" Thirty-four postmenopausal women with uterine prolapse received either no treatment, tibolone, E(2) or E(2) + medroxyprogesterone acetate (MPA) for 21 days, or a single dose of tibolone." | 5.12 | Levels of tibolone and estradiol and their nonsulfated and sulfated metabolites in serum, myometrium, and vagina of postmenopausal women following treatment for 21 days with tibolone, estradiol, or estradiol plus medroxyprogestrone acetate. ( Blok, LJ; Burger, CW; Hanifi-Moghaddam, P; Kloosterboer, HJ; Verheul, HA, 2007) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Rahn, DD | 1 |
Good, MM | 1 |
Roshanravan, SM | 1 |
Shi, H | 1 |
Schaffer, JI | 1 |
Singh, RJ | 1 |
Word, RA | 1 |
Vardy, MD | 1 |
Lindsay, R | 1 |
Scotti, RJ | 1 |
Mikhail, M | 1 |
Richart, RM | 1 |
Nieves, J | 1 |
Zion, M | 1 |
Cosman, F | 1 |
Verheul, HA | 1 |
Blok, LJ | 1 |
Burger, CW | 1 |
Hanifi-Moghaddam, P | 1 |
Kloosterboer, HJ | 1 |
Eriksson-Mjöberg, M | 1 |
Olund, A | 1 |
Carlström, K | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Preoperative Locally Applied Oestrogen in Postmenopausal Women With Pelvic Organ Prolapse: Changes in Subjective and Objective Outcome - a Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study[NCT03779633] | Phase 4 | 120 participants (Actual) | Interventional | 2017-02-02 | Completed | ||
Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic Floor[NCT01778985] | Phase 4 | 30 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Intraoperative estimated blood loss (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention
Intervention | mL (Mean) |
---|---|
Premarin | 285 |
Placebo | 285 |
Data represent ratio of total mRNA relative to postmenopausal external control. (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention
Intervention | ratio (Median) |
---|---|
Premarin | 2.19 |
Placebo | 0.37 |
Data represent ratio of total mRNA relative to postmenopausal external control. (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention
Intervention | ratio (Median) |
---|---|
Premarin | .92 |
Placebo | .37 |
Data represent ratio of total mRNA relative to postmenopausal external control. (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention
Intervention | ratio (Mean) |
---|---|
Premarin | .64 |
Placebo | .69 |
Data represent ratio of total mRNA relative to postmenopausal external control. (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention
Intervention | ratio (Mean) |
---|---|
Premarin | .74 |
Placebo | .51 |
(NCT01778985)
Timeframe: Baseline
Intervention | pg/mL (Mean) |
---|---|
Premarin | 11.1 |
Placebo | 8.4 |
(NCT01778985)
Timeframe: Time of surgery
Intervention | pg/mL (Mean) |
---|---|
Premarin | 7.8 |
Placebo | 11.6 |
(NCT01778985)
Timeframe: Baseline
Intervention | pg/mL (Mean) |
---|---|
Premarin | 18.0 |
Placebo | 18.5 |
(NCT01778985)
Timeframe: Time of surgery
Intervention | pg/mL (Mean) |
---|---|
Premarin | 22.8 |
Placebo | 24.9 |
Data represent ratio of total mRNA relative to postmenopausal external control. (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention
Intervention | ratio (Mean) |
---|---|
Premarin | .61 |
Placebo | .81 |
Will assess hydroxy-proline assays as index of amount of collagen (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention
Intervention | mg collagen per mg muscularis wet weight (Mean) |
---|---|
Premarin | 302.6 |
Placebo | 94.86 |
Data represent ratio of total mRNA relative to postmenopausal external control. (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention
Intervention | ratio (Mean) |
---|---|
Premarin | .78 |
Placebo | .69 |
Will assess vaginal wall histology - thicknesses of epithelium (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention
Intervention | microns (Mean) |
---|---|
Premarin | 413.9 |
Placebo | 314.1 |
Will assess vaginal wall histology - thicknesses of epithelium (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention
Intervention | microns (Mean) |
---|---|
Premarin | 550.5 |
Placebo | 314.1 |
Will assess vaginal wall histology - thickness of lamina propria. (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention
Intervention | microns (Mean) |
---|---|
Premarin | 1042.3 |
Placebo | 895.1 |
Will assess vaginal wall histology - thickness of lamina propria (NCT01778985)
Timeframe: Time of surgery, i.e. 6-8 weeks of intervention
Intervention | microns (Mean) |
---|---|
Premarin | 1133.4 |
Placebo | 895.1 |
Will assess vaginal wall histology - thicknesses of muscularis (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention
Intervention | microns (Mean) |
---|---|
Premarin | 5670.4 |
Placebo | 2807.1 |
Will assess vaginal wall histology - thicknesses of muscularis (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention
Intervention | microns (Mean) |
---|---|
Premarin | 7570.7 |
Placebo | 2807.1 |
Will assess zymograms for total matrix metalloprotease (MMP) 9 activity (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention
Intervention | Relative Units/mg protein (Mean) |
---|---|
Premarin | 8.97 |
Placebo | 56.73 |
Will assess zymograms for total matrix metalloprotease (MMP) 9 activity (NCT01778985)
Timeframe: Time of surgery, i.e. after 6-8 weeks of intervention
Intervention | Relative Units/mg protein (Mean) |
---|---|
Premarin | 37.03 |
Placebo | 132.34 |
3 trials available for estrone and Uterine Prolapse
Article | Year |
---|---|
Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial.
Topics: Administration, Intravaginal; Biopsy; Collagen; Collagenases; Double-Blind Method; Estradiol; Estrog | 2014 |
Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial.
Topics: Administration, Intravaginal; Biopsy; Collagen; Collagenases; Double-Blind Method; Estradiol; Estrog | 2014 |
Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial.
Topics: Administration, Intravaginal; Biopsy; Collagen; Collagenases; Double-Blind Method; Estradiol; Estrog | 2014 |
Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial.
Topics: Administration, Intravaginal; Biopsy; Collagen; Collagenases; Double-Blind Method; Estradiol; Estrog | 2014 |
Short-term urogenital effects of raloxifene, tamoxifen, and estrogen.
Topics: Aged; Atrophy; Double-Blind Method; Estradiol; Estrogens; Estrogens, Conjugated (USP); Estrone; Fema | 2003 |
Levels of tibolone and estradiol and their nonsulfated and sulfated metabolites in serum, myometrium, and vagina of postmenopausal women following treatment for 21 days with tibolone, estradiol, or estradiol plus medroxyprogestrone acetate.
Topics: Aged; Estradiol; Estrone; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Myometrium; Norp | 2007 |
1 other study available for estrone and Uterine Prolapse
Article | Year |
---|---|
Hormonal patterns in postmenopausal women during gynecological surgery.
Topics: 17-alpha-Hydroxyprogesterone; Aged; Analgesics, Opioid; Androstenedione; Anesthesia, Epidural; Anest | 1997 |